NCT02834507View on ClinicalTrials.gov

Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions

Parkinson's Disease (PD)

Interventions

DRUG

Placebo

Matching placebo capsules

DRUG

BIA 3-202

Capsules containing nebicapone 75 mg or 150 mg

DRUG

Comtan®

Capsules containing entacapone 200 mg

DRUG

Sinemet®

levodopa/carbidopa (Sinemet®) dose patient used to take

All Listed Sponsors

lead

Bial - Portela C S.A.

INDUSTRY

NCT02834507 - Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients | Biotech Hunter | Biotech Hunter